The main challenge for orphan drugs in Spain is access, which has become highly complex in recent years
In Conversation
Plasma-derived therapies are unique life-saving treatments based on a very special and finite raw material, therefore regulations should take this into account
mAbxience has a different business model than the majority of big biosimilars producers which have vast sales and marketing capabilities. We have a business-to-business (B2B) model,…
Genmab has strong, focused investment into its pipeline and capabilities and is now transitioning into a fully-integrated commercial company. We have made lots of progress, but…
It takes an average of seven years for a patient to see an audiologist from the onset of their hearing loss. However, the impact on the…
We have observed big improvements in terms of trust [in biosimilars] from both healthcare professionals and patients [in Spain] in the last few years
This region, and especially Denmark, is a beacon to the rest of the group for upcoming trends as well as a sandbox in which new solutions…
Clinical trials address a triple bottom line: increasing health, increasing knowledge, and increasing business
We want to go from a business-to-business (B2B) model ... to a business-to-consumer (B2C) specialty pharma model by having our own sales organization in key European…
The pandemic showed us the importance of putting patients at the centre, but we must ensure that they continue having access to medicines. If we all…
Countries that have been hit hard by the pandemic, especially in southern Europe, are now much more eager to learn from Denmark and our digitalised systems
In emergency care and triage, diagnosis and intervention time is crucially important. Blood gases are a foundational parameter for urgent care to understand the respiratory status…
